Supernus Pharmaceuticals Inc (SUPN)
31.32
+0.16
(+0.51%)
USD |
NASDAQ |
May 08, 16:00
31.32
0.00 (0.00%)
After-Hours: 20:00
Supernus Pharmaceuticals Research and Development Expense (Quarterly): 23.35M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 23.35M |
| September 30, 2023 | 22.66M |
| June 30, 2023 | 24.38M |
| March 31, 2023 | 21.21M |
| December 31, 2022 | 17.77M |
| September 30, 2022 | 19.55M |
| June 30, 2022 | 16.38M |
| March 31, 2022 | 20.84M |
| December 31, 2021 | 21.08M |
| September 30, 2021 | 19.65M |
| June 30, 2021 | 15.46M |
| March 31, 2021 | 34.28M |
| December 31, 2020 | 17.94M |
| September 30, 2020 | 16.84M |
| June 30, 2020 | 22.25M |
| March 31, 2020 | 18.94M |
| December 31, 2019 | 19.79M |
| September 30, 2019 | 16.94M |
| June 30, 2019 | 16.97M |
| March 31, 2019 | 15.39M |
| December 31, 2018 | 29.84M |
| September 30, 2018 | 20.42M |
| June 30, 2018 | 20.04M |
| March 31, 2018 | 18.91M |
| December 31, 2017 | 16.17M |
| Date | Value |
|---|---|
| September 30, 2017 | 12.98M |
| June 30, 2017 | 10.82M |
| March 31, 2017 | 9.601M |
| December 31, 2016 | 13.25M |
| September 30, 2016 | 7.868M |
| June 30, 2016 | 11.11M |
| March 31, 2016 | 10.56M |
| December 31, 2015 | 9.445M |
| September 30, 2015 | 9.129M |
| June 30, 2015 | 6.878M |
| March 31, 2015 | 3.683M |
| December 31, 2014 | 5.77M |
| September 30, 2014 | 4.657M |
| June 30, 2014 | 4.677M |
| March 31, 2014 | 4.482M |
| December 31, 2013 | 5.401M |
| September 30, 2013 | 3.779M |
| June 30, 2013 | 3.542M |
| March 31, 2013 | 4.522M |
| December 31, 2012 | 5.15M |
| September 30, 2012 | 8.306M |
| June 30, 2012 | 4.703M |
| March 31, 2012 | 5.358M |
| December 31, 2011 | 7.501M |
| September 30, 2011 | 8.425M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
15.46M
Minimum
Jun 2021
34.28M
Maximum
Mar 2021
20.33M
Average
19.65M
Median
Sep 2021
Research and Development Expense (Quarterly) Benchmarks
| Dynavax Technologies Corp | 14.12M |
| Ligand Pharmaceuticals Inc | 5.488M |
| Pacira BioSciences Inc | 19.46M |
| Esperion Therapeutics Inc | 17.74M |
| Collegium Pharmaceutical Inc | 0.00 |